Stocktoria
Ultragenyx Pharmaceutical Inc. RARE
Ultragenyx Pharmaceutical Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $673.0M | $560.0M | $434.0M | $363.3M | $351.4M | $271.0M | $103.7M | $51.5M | $2.6M | $133,000 |
| R&D expense | $750.0M | $698.0M | $648.0M | $705.8M | $497.2M | $412.1M | $357.4M | $294.0M | $231.6M | $183.2M |
| SG&A expense | $349.0M | $321.0M | $310.0M | $278.1M | $220.0M | $182.9M | $161.5M | $127.7M | $99.9M | $64.9M |
| Operating income | -$535.0M | -$536.0M | -$569.0M | -$648.9M | -$381.7M | -$330.1M | -$424.2M | -$371.4M | -$328.9M | -$248.0M |
| Income tax | $4.0M | $2.0M | -$2.0M | $5.7M | $1.0M | $1.2M | $3.3M | $514,000 | -$16.2M | $35,000 |
| Net income | -$575.0M | -$569.0M | -$607.0M | -$707.4M | -$454.0M | -$186.6M | -$402.7M | -$197.6M | -$302.1M | -$245.9M |
| EPS (diluted) | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 | $-3.07 | — | — | — | — |
| Operating cash flow | -$466.0M | -$414.0M | -$475.0M | -$380.5M | -$338.7M | -$132.2M | -$345.4M | -$290.6M | -$253.8M | -$161.0M |
| Free cash flow | -$472.0M | -$421.0M | -$519.0M | -$496.6M | -$411.8M | -$176.1M | -$370.2M | -$294.6M | -$256.6M | -$171.2M |
| Cash & equivalents | $421.0M | $174.0M | $214.0M | $132.9M | $307.6M | $713.5M | $433.6M | $113.4M | $100.5M | $161.1M |
| Inventory | $52.0M | $45.0M | $34.0M | $26.8M | $16.2M | $13.0M | $11.5M | $7.1M | $757,000 | — |
| Total assets | $1.5B | $1.5B | $1.5B | $1.5B | $1.5B | $1.8B | $1.1B | $719.6M | $490.8M | $540.6M |
| Total liabilities | $1.6B | $1.2B | $1.2B | $1.2B | $599.8M | $605.2M | $481.7M | $110.7M | $107.3M | $66.7M |
| Shareholders' equity | -$80.0M | $255.0M | $275.0M | $352.0M | $922.6M | $1.2B | $653.8M | $608.9M | $383.5M | $474.0M |
Growth · year-over-year · Revenue CAGR 158%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +20.2% | +29.0% | +19.5% | +3.4% | +29.7% | +161.3% | +101.4% | +1871.5% | +1863.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.